In:
Blood, American Society of Hematology, Vol. 123, No. 3 ( 2014-01-16), p. 356-365
Kurzfassung:
CD33 expression levels in AML correlate with specific disease characteristics. Potent cytotoxicity against primary AML blasts is mediated by a CD33/CD3-bispecific antibody.
Materialart:
Online-Ressource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood-2013-08-523548
Sprache:
Englisch
Verlag:
American Society of Hematology
Publikationsdatum:
2014
ZDB Id:
1468538-3
ZDB Id:
80069-7